RSRomolo Sandrini

Romolo Sandrini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Romolo Sandrini has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Childhood Adrenocortical Tumours: a Review

    by Rosana Marques-Pereira, Luiz DeLacerda, Hadriano M Lacerda, Edson Michalkiewicz, Fabiano Sandrini, Romolo Sandrini

    Childhood adrenocortical tumour (ACT) is not a common disease, but in southern Brazil the prevalence is 15 times higher than in other parts of the world. One hundred and thirty-seven patients have been identified and followed by our group over the past four decades. Affected children are predominantly girls, with a female-to-male ratio of 3.5:1 in patients below 4 years of age. Virilization alone (51.6%) or mixed with Cushing's syndrome (42.0%) was the predominant clinical picture observed in these patients. Tumours are unilateral, affecting both glands equally. TP53 R337H germline mutations underlie most childhood ACTs in southern Brazil. Epidemiological data from our casuistic studies revealed that this mutation has ~10% penetrance for ACT. Surgery is the definitive treatment, and a complete resection should always be attempted. Although adjuvant chemotherapy has shown some encouraging results, its influence on overall outcome is small. The survival rate is directly correlated to tumour size; patients with small, completely excised tumours have survival rates close to 90%, whereas in those patients with inoperable tumours and/or metastatic disease it is less than 10%. In the group of patients with large, excisable tumours, half of them have an intermediate outcome. Recent molecular biology techniques and genomic approaches may help us to better understand the pathogenesis of ACT, the risk of developing a tumour when TP53 R337H is present, and to predict its outcome. An ongoing pilot study consisting of close monitoring of healthy carriers of the TP53 R337H mutation - siblings and first-degree relatives of known affected cases - aims at the early detection of ACTs and an improvement of the cure rate.


  • Open Access

    Tratamento do tumor do córtex adrenal na infância

    by Rosana Marques Pereira, Edson Michalkiewicz, Mara Albonei Pianovski, Susana Nesi França, Margaret C.S. Boguszewski, Izrail Cat, Luiz de Lacerda Filho, Romolo Sandrini

    O tumor do córtex adrenal (TCA) na infância é raro. Entretanto, no Paraná sua incidência é 15 vezes maior do que a observada em outros países. A mutação germinativa R337H TP53, presente em mais de 95% dos nossos pacientes, provavelmente está relacionada à maior incidência. Cento e vinte e cinco pacientes foram tratados no período de 1966 a 2003. A cirurgia é o único tratamento curativo. Em nossa experiência, tumores no estádio I, ausência de spillage durante a cirurgia e ausência de trombo são parâmetros relacionados à maior sobrevida. Dados preliminares mostram que a associação de etoposídeo, doxorrubicina, cisplatina e mitotano produziu remissão completa do tumor e/ou das metástases em alguns pacientes. Os efeitos colaterais destas drogas são comuns e pode ocorrer insuficiência adrenocortical. As doses de reposição de glicocorticóides e mineralocorticóides devem ser 2 a 3 vezes maiores que as doses fisiológicas.


  • Open Access

    Tumores do córtex adrenal na infância

    by Rosana Marques Pereira, Edson Michalkiewicz, Fabiano Sandrini, Bonald C. Figueiredo, Mara Pianovski, Susana Nesi França, Margaret C.S. Boguszewski, Orival Costa, Izrail Cat, Luiz de Lacerda Filho, et al.

    O tumor do córtex adrenal (TCA) na infância é raro. Entretanto, no Paraná sua incidência é 15 vezes maior do que a observada em outros países. Descrevemos as características clínicas, laboratoriais, tratamento e evolução de 125 pacientes atendidos em uma única instituição no Paraná. A média de idade ao diagnóstico foi de 4,3 anos, com uma relação feminino:masculino de 2,6:1. As formas clínicas mais comuns foram virilização isolada (51,2%) e virilização e síndrome de Cushing (42%). Em 4,8% dos casos, os tumores foram não-funcionantes. Dois pacientes (1,6%) apresentaram síndrome de Cushing isolado e 1 (0,8%) síndrome de Conn. Hipertensão arterial ocorreu em 56% dos pacientes. O único tratamento curativo é a cirurgia. Os dados da nossa casuística mostram que estádio clínico 1 do TCA, ausência de trombo intra-venoso e ausência de spillage durante a cirurgia estão associados a uma maior sobrevida.


  • Clinical characteristics of small functioning adrenocortical tumors in children

    by Edson L. Michalkiewicz, Romolo Sandrini, Michael F. Bugg, Lilian Cristofani, Eliane Caran, Ana Maria S. Cardoso, Luiz de Lacerda, Raul C. Ribeiro

    Twenty of 67 children registered on the International Registry of Childhood Adrenocortical Tumors between May 1988 and December 1994 had small adrenocortical tumors (defined for this study as measuring ≤ 200 cm3 and/or weighing ≤ 100 g). We reviewed the records of these 20 patients to characterize the clinical and pathologic findings and outcomes of children with small adrenocortical tumors. Median patient age was 2 years (range, 4 months to 5 years). There was only one boy. All had clinical signs of virilization, and seven had signs or symptoms of Cushing syndrome. A median 5.5 months (range, 1–40 months) had elapsed between the first signs of endocrine dysfunction and diagnosis. All tumors were surgically resected. Tumor volume was 3.3–195 cm3 (median, 38.7 cm1), and weight was 3.7–100 g (median, 36 g). Tumor samples were histologically reviewed in 18 cases. Eight were adenomas, and 10 were carcinomas (6 low grade and 4 high grade). Pathology records described tumor with diagnostic features of adrenocortical carcinoma in two patients. One patient received mitotane for 8 months after surgery. Only one patient had recurrent disease, which was detected 6 months after diagnosis and proved rapidly fatal. Another has been lost to follow‐up. The remaining 18 patients are alive with no evidence of disease at a median 2.3 years (range, 6 months to 6.1 years) after diagnosis. Our data suggest that children with small adrenocortical tumors have an excellent prognosis with surgery as the sole therapy, regardless of tumor histiotype. Med. Pediatr. Oncol. 28:175–178.